Company Overview

In 2002, Ferring Pharmaceuticals launched Menopur, an infertility treatment, providing a strong foundation for further progress in ART. Since that time, the company has expanded its offerings to include Bravelle, Endometrin, Novarel, Choragon, Decapeptyl, Choragon, Brevactid (u-hCG), Lutinus, Endometrin, Lutrepulse, Lutrelef, Menogon, Repronex, and Rekovelle.

Ferring Pharmaceuticals is headquartered in Switzerland and is a specialty biopharmaceutical company. The company develops and markets products in the areas of reproductive health, urology, gastroenterology, and endocrinology. The privately owned company was founded in 1950 and has become a global presence with offices in over 50 countries. It employs approximately 7,000 individuals and has production facilities in several European countries, including Israel, China, Mexico, and Argentina. R&D facilities are located in Denmark, the U.S., Israel, India, and China.

Company's Business Segments

• Reproductive Medicine & Maternal Health : This segment deals with fertility, safe birth, and preterm birth.
• Gastroenterology : This segment deals with Inflammatory bowel diseases (IBDs) and Clostridioides difficile infection.
• Urology & Uro-Oncology : This segment deals with Bladder cancer, prostate cancer, Bedwetting, and Nocturia.